EPO Patents = 3

Forward Citations = 201

Loading Chart...

16 inventors (with patents filed for the assignee):

Guy J Laidig (4 out of 31 patents)

Mark Stephen Smyth (3 out of 39 patents)

Craig M Crews (2 out of 33 patents)

4. John H Musser (2 out of 113 patents)

5. Ronald T Borchardt (2 out of 7 patents)

6. Barry A Bunin (2 out of 6 patents)

7. Han-Jie Zhou (1 out of 37 patents)

8. Francesco Parlati (1 out of 21 patents)

9. Mark K Bennett (1 out of 35 patents)

10. Congcong M Sun (1 out of 6 patents)

11. Kevin D Shenk (1 out of 27 patents)

12. Monette Aujay (1 out of 5 patents)

13. Mark Nguyen Ho (1 patent)

14. Fabiana N Fonseca (1 patent)

15. Evan R Lewis (0 patent)

5 patents: Sort by Forward Citations

1. 7741432 - Substrate for Rpn11 enzymatic activity (2010-06-22),

2. 7687456 - Compounds for enzyme inhibition (2010-03-30),

3. 7491704 - Compounds for enzyme inhibition (2009-02-17),

4. 7417042 - Compounds for enzyme inhibition (2008-08-26),

5. 7232818 - Compounds for enzyme inhibition (2007-06-19),

Proteolix, Inc. is a biopharmaceutical company focused on the development of novel therapies for the treatment of cancer. The company's lead product is a proteasome inhibitor with promising results in clinical trials for multiple myeloma and other hematologic malignancies. Proteolix is dedicated to advancing the field of oncology through innovative research and strategic partnerships.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

5 Patents

#734 in San Francisco, CA

#11,721 in California

#50,165 in US

San Francisco, CA, United States of America

Proteolix, Inc.